Catalog No.
Product Name
Application
Product Information
Citations
-
PSMA ligand
PNT2001 is a potent prostate-specific membrane antigen (PSMA) ligand, exhibiting an IC50 of 3.1 nM. This compound enhances cellular internalization, making it a valuable tool for targeting PSMA in prostate cancer research. Additionally, PNT2001 can be labeled with 177Lu and 225Ac, facilitating the development of radiolabeled therapies for prostate cancer treatment and diagnostic applications. -
Precursor
PSMA I&S is a key precursor for the synthesis of 99mTc-labeled PSMA-targeting ligands. This compound facilitates the generation of radiolabeled agents that selectively bind to the prostate-specific membrane antigen (PSMA), making it valuable for imaging and therapeutic applications in prostate cancer research. Its role in the development of novel radiopharmaceuticals enhances the ability to study PSMA expression in various biological contexts. -
PSMA Near-infrared Optical Probe
Zopocianine is a near-infrared optical probe targeting prostate-specific membrane antigen (PSMA). This compound selectively binds to PSMA expressed on the surface of cancer cells, facilitating receptor-mediated endocytosis and subsequent accumulation within acidic endosomes. Zopocianine is particularly effective for visualizing small tumors, primary prostate tumors, and locoregional metastases, making it a valuable tool in fluorescence-guided surgery for achieving negative tumor margins. Its applications are primarily in the field of prostate cancer research. -
PSMA Ligand
PSMA binder-2 is a potent ligand targeting Prostate-Specific Membrane Antigen (PSMA), facilitating the synthesis of Ac-PSMA-trillium, which exhibits enhanced binding and pharmacokinetic properties. This versatile compound can be modified with various radioactive isotopes for different applications; when labeled with 111In, it serves effectively as a DOTA chelating and imaging agent. Alternatively, when conjugated with 225Ac, it acts as a Macropa chelator, proving valuable for targeted radionuclide therapy (TRT) in the research of metastatic castration-resistant prostate cancer (mCRPC). -
PSMA Radioactive Inhibitor
PSMA–DA1 is a radioactive inhibitor targeting Prostate-Specific Membrane Antigen (PSMA). It serves as a promising radiotheranostic agent for imaging and treating PSMA-expressing tumors. Its specificity for PSMA makes it a valuable tool in the research of prostate cancer diagnosis and therapy, enabling the development of effective targeted treatment strategies. -
PSMA Inhibitor
MIP-1072 is a selective inhibitor of prostate-specific membrane antigen (PSMA) that targets the enzyme's glutamate carboxypeptidase activity. With a Ki value of 4.6 nM, MIP-1072 demonstrates significant potency in inhibiting PSMA, making it a valuable tool in prostate cancer research. Its application is particularly relevant for studies focused on the role of PSMA in tumor progression and targeted therapies. -
PSA-activated Protoxin
Topsalysin is a PSA-activated protoxin that functions as a pore-forming protein, specifically a synthetic proaerolysin fusion protein modified to target human prostate-specific antigen (PSA). It demonstrates significant tumor-suppressive effects in mouse models, making it a valuable tool for studying prostate cancer biology. Its unique mechanism allows for selective targeting of PSA-expressing tissues, providing insights into therapeutic approaches for prostate cancer treatment. -
PSMA Ligand
PSMA Ligand 1 is a potent PSMA ligand that exhibits an IC50 of 26.74 nM. This compound has been radiolabeled with [18F], making it a suitable candidate for use as a PET tracer in imaging studies. Its primary applications include aiding in the diagnosis and monitoring of prostate cancer, facilitating innovative research in oncology and molecular imaging. -
PSMA Ligand
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that functions as a tumor retention agent and imaging agent while reducing renal uptake. It selectively binds to PSMA on prostate cancer cells, facilitating entry through clathrin-dependent endocytosis, which results in increased tumor retention and decreased renal accumulation. PDI2 is valuable for research in prostate cancer and castration-resistant metastatic prostate cancer, particularly in the context of SPECT diagnostic imaging and radiotheranostics. -
PSMA Inhibitor
MIP-1095 is a potent inhibitor of prostate-specific membrane antigen (PSMA), specifically targeting its glutamate carboxypeptidase activity with a Ki of 0.24 nM. This compound is valuable in research applications focused on prostate cancer, facilitating studies on PSMA's role in tumor progression and its potential as a therapeutic target. MIP-1095 is essential for the development of PSMA-targeted diagnostics and therapeutics. -
PSMA Inhibitor
PSMA-IN-4 is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting an IC50 value of 1.2 μM. This compound effectively interferes with PSMA activity, making it a valuable tool in research focused on prostate cancer diagnostics and therapeutics. Its specificity and potency support investigations into PSMA's role in tumor biology and its potential as a therapeutic target. -
Anti-PSMA Antibody
Capromab is a monoclonal antibody targeting the intracellular domain of prostate-specific membrane antigen (PSMA). It exhibits specificity for necrotic cells with compromised membranes and does not undergo internalization upon binding. Capromab is utilized in research focused on prostate cancer, aiding in studies related to tumor progression and targeted therapies. -
PSMA Ligand
PSMA Ligand 3 is a ligand specifically targeting Prostate-Specific Membrane Antigen (PSMA). Its primary function is to bind to PSMA, facilitating the detection and imaging of prostate cancer cells. This compound is valuable in cancer research, particularly in the study of prostate cancer diagnostics and therapy. -
PSMA Binder
PSMA binder-3 is a selective binder for Prostate-Specific Membrane Antigen (PSMA), a key target in prostate cancer research. This high-affinity ligand exhibits strong binding capabilities that facilitate the study of PSMA's role in tumor biology and therapeutic targeting. It is an essential tool for applications in imaging and drug development related to prostate cancer. -
PSMA Probe
PSMA-trillium is a PSMA-targeting compound that features a PSMA binder, a Macropa chelating molecule, and a pharmacokinetics modifier. This non-radioactive derivative of Actinium-225-PSMA-Trillium (BAY 3563254) offers enhanced PSMA targeting and optimized pharmacokinetic properties. PSMA-trillium effectively binds to Ac via the Macropa chelator and serves as a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC). It is a valuable tool for research into targeted therapies for prostate cancer. -
PSMA Tracer
BQ0413 is a potent PSMA tracer with a dissociation constant (KD) of 89 pM, demonstrating strong affinity for the prostate-specific membrane antigen. This compound exhibits efficient cellular uptake and a notable internalization rate of 44% in PC3-pip cells, making it suitable for research applications in tumor imaging. When radiolabeled with 99mTc, BQ0413 serves as an effective imaging agent for prostate cancer in preclinical studies. -
PSMA Ligand
PSMA-N5 is a potent PSMA ligand, exhibiting a Ki value of 0.71 nM. This compound serves as a PET radiotracer specifically for imaging prostate cancer, facilitating the visualization of tumors. PSMA-N5 is valuable for research applications in prostate cancer and other malignancies associated with prostate-specific membrane antigen. -
PSMA Inhibitor
PSMA-IN-2 is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA) with a Ki value of 1.07 nM. This compound exhibits promising in vivo near-infrared (NIR) imaging properties at an emission wavelength of 1088 nm and an excitation wavelength of 808 nm. PSMA-IN-2 is particularly applicable in NIRII image-guided tumor resection surgeries in models of PSMA-positive tumors, making it a valuable tool for cancer research and therapeutic interventions. -
PSMA Inhibitor
PSMA-IN-3 is a high-affinity inhibitor of Prostate-Specific Membrane Antigen (PSMA), demonstrating an IC50 value of 13 nM. This compound is particularly relevant for the development of 18F-labeled radioligands for positron emission tomography (PET) imaging to detect PSMA expression in prostate cancer. Researchers can utilize PSMA-IN-3 for studies aimed at advancing diagnostic imaging and therapeutic strategies in oncology. -
PSMA Inhibitor
DCFBC is a potent prostate-specific membrane antigen (PSMA) inhibitor, primarily utilized for small animal positron emission tomography (PET) imaging applications. Labeled with fluorine-18, [18F]DCFBC demonstrates preferential uptake in PSMA-expressing tumors, particularly in PIP tumors, while showing minimal uptake in FLU tumors. Additionally, while high accumulation in the kidneys and bladder is observed, the washout of radioactivity is faster compared to PIP tumors. This specificity positions [18F]DCFBC as a valuable tool for studying prostate cancer and assessing PSMA-targeted therapies. -
PSMA Inhibitor
(R)-Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting significant antitumor activity. It is primarily utilized in research focused on prostate cancer, contributing to the understanding of targeted therapeutic approaches. This compound serves as a valuable tool for investigating the role of PSMA in cancer biology and evaluating efficacy in preclinical studies. -
PSMA Ligand
PSMA-MAL-5 is a prostate-specific membrane antigen (PSMA) ligand that covalently binds to Cys466 of the PSMA protein. This compound demonstrates significant biological activity, including high radiostability and tumor uptake when labeled with 177Lu and 225Ac. PSMA-MAL-5 is also effective in inhibiting tumor growth, making it suitable for applications in SPECT/CT imaging and radionuclide therapy for prostate cancer. -
Precursor of PSMA Ligands
PSMA precursor-1 is a key intermediate in the synthesis of prostate-specific membrane antigen (PSMA) ligands and fluorescent probes. It is utilized for the detection of PSMA in prostate cancer cell lines, specifically LNCaP and PC3. This compound plays a significant role in the development of targeted imaging agents and therapeutic strategies for prostate cancer research. -
SIK2/SIK3 Inhibitor
GLPG3970 is a selective inhibitor of SIK2 and SIK3, targeting these kinases to modulate their activity. This compound demonstrates significant potential in studying inflammatory responses and autoimmune diseases, contributing to the understanding of their underlying mechanisms and potential therapeutic approaches. Its role as a first-in-class inhibitor positions GLPG3970 as a valuable tool in biomedical research focused on these critical areas. -
SIK2/SIK3 Inhibitor
SK-124 is an orally active inhibitor of salt-inducible kinases 2 and 3 (SIK2/SIK3). It selectively inhibits SIK2 and SIK3, leading to enhanced levels of pro-peptide of type I collagen (P1NP) and C-terminal telopeptide of type I collagen (CTX). This modulation results in increased bone formation and bone mass, making SK-124 a valuable tool for research on bone metabolism and associated disorders. -
SIK Inhibitor
YKL-06-062 is a selectively potent inhibitor of salt-inducible kinases (SIKs), demonstrating IC50 values of 2.12 nM, 1.40 nM, and 2.86 nM for SIK1, SIK2, and SIK3, respectively. This compound is pivotal for research involving cellular stress responses, inflammatory processes, and metabolic regulation. Its specificity and efficacy make it a valuable tool for exploring SIK-related signaling pathways in various biological contexts. -
Sik3 Inhibitor
Pterosin B is an orally active indanone and a selective inhibitor of the SIK3 signaling pathway. It has demonstrated key biological activities, including the inhibition of Klf5 expression and a reduction in β-amyloid deposition, making it relevant in Alzheimer's disease research. Additionally, Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mouse models, while also inhibiting cardiomyocyte hypertrophy and improving cognitive impairment and glycemic control. This compound is valuable for studies related to arthritis, neurodegenerative disorders, pathological cardiac hypertrophy, and diabetes. -
SIK Inhibitor
WH-4-025 is an inhibitor of salt-inducible kinases (SIKs), which play a critical role in regulating various cellular processes, including metabolism, inflammation, and transcription. This compound has demonstrated significant biological activity by modulating SIK signaling pathways, making it a valuable tool for investigating the roles of SIKs in cellular response to environmental stressors. WH-4-025 is suitable for research applications aimed at understanding diseases linked to SIK dysregulation, such as metabolic disorders and cancer. -
SIK2 Inhibitor
SIC-19 is a selective inhibitor of SIK2, promoting its degradation through the ubiquitination pathway. This compound exhibits significant antiproliferative activity against cancer cells and enhances the sensitivity of these cells to PARP inhibitors, including Olaparib. Additionally, SIC-19 demonstrates efficacy in ovarian cancer organoids and xenograft models, making it a valuable tool for cancer research and therapeutic development. -
SIK Inhibitor
MR22 is a potent inhibitor of salt-inducible kinases (SIKs), demonstrating excellent selectivity in a representative kinase panel, while lacking activity against STE group kinases. This compound effectively induces centrosome dissociation and contributes to cell-cycle arrest in ovarian cancer cells. MR22 holds potential for research in cancer biology and the therapeutic targeting of SIK-related pathways. -
SIK Inhibitor
SIKs-IN-1 is a pyrimidine-5-carboxamide derivative that functions as an inhibitor of Salt-inducible kinases (SIKs). It modulates the balance between M1 and M2 macrophages, playing a crucial role in the inflammatory response. SIKs-IN-1 effectively inhibits SIK activity, leading to the upregulation of the anti-inflammatory cytokine IL-10 and the downregulation of the pro-inflammatory cytokine IL-12. This compound demonstrates significant anti-inflammatory effects in models of DSS-induced colitis, making it valuable for research into inflammatory diseases. -
SIK1/2 Inhibitor
SIK2-IN-3 is a selective inhibitor of SIK1 and SIK2, with IC50 values of 0.128 μM and 0.084 μM, respectively. This compound effectively inhibits the phosphorylation of CRTC3 and reduces pro-inflammatory cytokine production in myeloid cells. SIK2-IN-3 demonstrates potential in mitigating systemic and tissue inflammatory responses, as evidenced by its efficacy in a mouse anti-CD40 colitis model, making it a valuable tool for research in inflammation and immune response mechanisms. -
SIK2/3 Inhibitor
SIK2/3-IN-1 is a selective inhibitor of Salt-Inducible Kinases 2 and 3 (SIK2/3). It has demonstrated significant efficacy in inhibiting tumor growth in the MV4-11 acute myeloid leukemia (AML) mouse xenograft model, while maintaining animal body weight. This compound is valuable for investigating MEF2C-dependent pathways in acute myeloid leukemia research. -
CD36 Ligand
1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine is a glycerophosphorylcholine that targets scavenger receptor class B, specifically CD36. This compound accumulates at sites of oxidative stress in vivo and is implicated in the molecular mechanisms of tumor apoptosis. Its interaction with oxidized phospholipids (oxPLs) suggests potential applications in cancer research and studies related to oxidative stress and inflammation. -
CD36 Inhibitor
1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC is a unique oxidized phospholipid that functions as a potent CD36 inhibitor. It features palmitic acid at the sn-1 position and 13(S)-HODE at the sn-2 position, allowing it to interfere with the binding of 125I-NO2-LDL to CD36-transfected 293 cells, exhibiting an IC50 value greater than 200 μM. This compound is useful for research applications exploring lipid interactions and receptor signaling pathways associated with CD36. -
STING Inhibitor
SN-011 is a selective inhibitor of the STING pathway, displaying an IC50 of 76 nM. By competing with cyclic dinucleotides (CDNs) for the binding site on the STING dimer, SN-011 effectively prevents CDN binding and subsequent STING activation. This compound is valuable for investigating STING-mediated autoimmune and inflammatory diseases, offering insights into therapeutic strategies targeting this critical signaling pathway. -
STING Inhibitor
STING-IN-2 is a potent covalent inhibitor of Stimulator of Interferon Genes (STING), effectively targeting both mouse and human STING isoforms. This compound is instrumental in studying the role of STING in autoinflammatory diseases, facilitating the exploration of therapeutic interventions. Its ability to modulate STING activity makes it a valuable tool for researchers investigating immune response and signaling pathways. -
Second Messenger/STING Agonist
Cyclic-di-GMP disodium functions as a STING agonist and serves as a crucial bacterial second messenger. It orchestrates various bacterial behaviors such as motility, virulence, biofilm formation, and cell cycle regulation. Additionally, cyclic-di-GMP disodium exhibits anti-cancer activity by inhibiting cell proliferation and promoting CD4 receptor expression along with inducing cell cycle arrest. This compound is valuable for applications in cancer research. -
STING Activator
cGAMP disodium, a potent STING activator, functions as an endogenous second messenger that triggers the production of interferons in response to cytosolic DNA. It initiates the stimulator of interferon genes (STING) pathway, resulting in an immune response marked by the production of type I interferons and various immune mediators. This compound is widely used in research focused on innate immunity, cancer immunotherapy, and understanding viral infections. -
STING Activator
STING agonist-12 (Compound 53) is a potent agonist that activates the human stimulator of interferon genes (STING) pathway, exhibiting an EC50 value of 185 nM. This compound serves as a valuable tool for immunological research, particularly in studying innate immune responses and antitumor immunity. Its ability to modulate STING activity makes it a promising candidate for assessing therapeutic strategies in cancer and infectious diseases. -
STING Molecular Glue
NVS-STG2 is a molecular glue that targets the STING receptor by binding to the interstitial regions of adjacent STING dimers, thereby enhancing STING signaling. This compound promotes the activity of cGAMP, leading to the formation of larger and more stable oligomers, which amplifies the immune response. NVS-STG2 has demonstrated significant antitumor effects in preclinical animal models, making it a valuable tool for cancer immunotherapy research. -
STING Agonist
STING agonist-20 is a potent agonist of the STING pathway, which plays a critical role in the innate immune response. This compound is utilized in the synthesis of XMT-2056, serving as an important tool in cancer research and the investigation of inflammatory and immune-related diseases. Its application as a vaccine adjuvant allows for enhanced immune activation, making it a valuable reagent in immunotherapy studies. -
STING Agonist
STING Agonist-22 (CF501) is a potent non-nucleotide agonist targeting the stimulator of interferon genes (STING). This compound effectively activates STING to induce a type I interferon (IFN-I) response and drive the production of proinflammatory cytokines. STING Agonist-22 serves as an adjuvant to enhance protein vaccine efficacy, promoting robust and sustained immune protection. It is particularly relevant for research on SARS-CoV-2 variants and related sarbecovirus diseases. -
STING Antagonist
STING antagonist-1 is a selective antagonist of the Stimulator of Interferon Genes (STING) pathway, exhibiting an IC50 of 3.8 nM. This compound is valuable for research applications related to autoimmune and inflammatory diseases, allowing for the investigation of STING-mediated cellular responses and therapeutic interventions. -
Second Messenger/STING Agonist
Cyclic-di-GMP diammonium is a second messenger with significant activity as a STING agonist. It plays a crucial role in regulating bacterial growth, motility, virulence, biofilm formation, and cell cycle progression. In addition to its bacterial applications, cyclic-di-GMP diammonium demonstrates anti-cancer properties, promoting cell cycle arrest and increasing CD4 receptor expression. This reagent is valuable for investigations in cancer research. -
STING Inhibitor
LB244 is a STING inhibitor that functions by modulating the STING signaling pathway to reduce inflammation. It exhibits a potent inhibitory effect (EC50 = 0.8 μM) on STING-dependent inflammatory responses. While LB244 shows promising potential in preclinical studies, its pharmacokinetic profile suggests limited oral bioavailability in murine models. This compound is suitable for research applications focused on understanding STING-related inflammatory disorders. -
STING Agonist
E7766 diammonium salt is a macrocycle-bridged STING agonist that exhibits a dissociation constant (Kd) of 40 nM. This compound demonstrates potent pan-genotypic activity and significant antitumor effects, making it a valuable tool for cancer immunotherapy research. It is suitable for studies focused on modulating the STING pathway to enhance immune responses against tumors. -
STING Agonist
IACS-8803 disodium is a potent cyclic dinucleotide and a selective STING agonist. It activates the STING pathway, leading to enhanced immune responses against tumors. This compound is utilized in research related to cancer immunotherapy and the modulation of immune signaling pathways. -
STING Agonist
Dazostinag disodium is a potent STING agonist that activates the STING signaling pathway, leading to the production of type I interferons. This compound enhances immune responses, resulting in complete tumor regressions and the establishment of long-lasting memory T-cell immunity. Dazostinag disodium is valuable for research applications focused on cancer immunotherapy and the modulation of the immune system. -
STING Agonist
diABZI-C2-NH2 is a potent STING (Stimulator of Interferon Genes) agonist that features a primary amine group. This compound activates the STING pathway, leading to enhanced type I interferon production and immune response modulation. diABZI-C2-NH2 is valuable for research applications focused on immunotherapy, autoimmunity, and infectious disease, making it a key tool in studying the role of STING in immune signaling.
